PAUL RUESTOW, M.D.
Endocrinology, Diabetes & Metabolism Physician in CHICAGO, Illinois. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PAUL RUESTOW, M.D. filed 5,177 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in CHICAGO, Illinois, prescribing 82% generic.
- 5K
- Part D claims, 2023
- 82%
- generic prescribing
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PAUL RUESTOW, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
5,177 Top 6% higher than 94% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
PAUL RUESTOW, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about PAUL RUESTOW, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Illinois
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Illinois providers
Endocrinology, Diabetes & Metabolism Physician share within Illinois
Endocrinology, Diabetes & Metabolism Physician is one of the more visible NUCC categories in Illinois
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
Specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PAUL RUESTOW, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 2545 S KING DR, CHICAGO, IL, 60616, with a listed phone of (312) 842-7117. NPI 1700896065 was issued on 08/09/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what RUESTOW most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 5,177 prescription claims written by this provider, covering 441 Medicare beneficiaries and totaling roughly $940K in drug spend, split 18% brand-name and 82% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1700896065 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 08/09/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PAUL RUESTOW, M.D.'s current license status, disciplinary history, and board certifications with the Illinois Department of Financial and Professional Regulation in Illinois before relying on this page for a clinical or care decision.
How we sourced this profile
License & disciplinary context — Illinois IDFPR 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~42K Illinois medical licensees in 2023 — they are NOT specific to PAUL RUESTOW, M.D.. To verify PAUL RUESTOW, M.D.'s current license status, search the IDFPR public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
IDFPR publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Illinois disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
18% brand-name claims vs 82% generic, on 5,177 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 12,392
- Total Day Supply
- 366,011
- Brand vs Generic
- 18% brand / 82% generic
- Brand Drug Cost
- $856K
- Generic Drug Cost
- $76K
- Antibiotic Claims
- 14
Patient Demographics
- Average Patient Age
- 74.8 years
- Avg HCC Risk Score
- 1.65
- Gender Split
- 64% female / 36% male
- Age Distribution
- <65: 31, 65-74: 196, 75-84: 153, 85+: 61
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PAUL RUESTOW, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Atorvastatin Calcium
Atorvastatin Calcium
625 claims
- Levothyroxine Sodium
Levothyroxine Sodium
260 claims
- Amlodipine Besylate 241
Amlodipine Besylate
241 claims
- Losartan Potassium 209
Losartan Potassium
209 claims
- Hydrochlorothiazide 166
Hydrochlorothiazide
166 claims
- Ozempic 157
Ozempic
157 claims
- Methimazole 144
Methimazole
144 claims
- Metformin Hcl 137
Metformin Hcl
137 claims
| Drug | Claims |
|---|---|
| Atorvastatin Calcium | 625 |
| Levothyroxine Sodium | 260 |
| Amlodipine Besylate | 241 |
| Losartan Potassium | 209 |
| Hydrochlorothiazide | 166 |
| Ozempic Semaglutide | 157 |
| Methimazole | 144 |
| Metformin Hcl | 137 |
| Metoprolol Succinate | 123 |
| Lisinopril | 120 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How PAUL RUESTOW, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
PAUL RUESTOW, M.D.'s 5,177 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Illinois
Other clinicians with the same primary specialty enrolled in Illinois, drawn from the same CMS NPPES roster as RUESTOW.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Illinois
Frequently Asked Questions
What is PAUL RUESTOW, M.D.'s specialty? ▼
How much does PAUL RUESTOW, M.D. prescribe under Medicare Part D? ▼
Where is PAUL RUESTOW, M.D. located? ▼
What is PAUL RUESTOW, M.D.'s NPI number? ▼
Does PAUL RUESTOW, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does PAUL RUESTOW, M.D. prescribe most often? ▼
Does PAUL RUESTOW, M.D. accept Medicare? ▼
How can I verify PAUL RUESTOW, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology